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Introduction
Invasive aspergillosis (IA) has emerged as a major
life-threatening infectious complication in patients
with prolonged neutropenia and in solid-organ trans-
plant recipients [1]. The frequency of IA in kidney
transplantation varies between 0.5% and 2.2% [2]. The
high case-fatality rate of 62% overall in renal trans-
plant recipients and up to 88% in disseminated disease
emphasizes the need for more accurate diagnostic tech-
niques and better therapeutic options [3]. Although
the recent introduction of new antifungal agents, such
as voriconazole and caspofungin, offers new opportu-
nities in the treatment of IA [4,5], optimal treatment
and management of these patients remains problematic
and controversial.
We discuss a case of IA with predominant thyroid
and myocardial involvement after kidney transplanta-
tion, focusing on adequate therapy, duration of treat-
ment and surveillance.
Case
A 49-year-old patient with diabetic nephropathy
received a cadaveric renal allograft. Cytomegalovirus
status was negative for the recipient and positive for
the donor. The initial immunosuppression consisted
of cyclosporin (trough levels: 350–450 mg/l), myco-
phenolate mofetil (2 1500mg daily) and prednisone
(50mg daily). Initial graft function was satisfactory;
serum creatinine decreased from 7.8mg/dl (696 mmol/l)
to 2.4mg/dl (216 mmol/l) within 9 days. Two biopsy-
proven acute rejections, a steroid-resistant interstitial
rejection on day 43 and a vascular rejection on day 101,
were treated with anti-T-lymphocyte globulin (ATG:
4mg/kg for 7 days) and anti-CD3 antibodies (OKT3:
5mg for 7 days), respectively. Additionally, cyclo-
sporin was replaced by tacrolimus on day 102 (trough
levels: 12–15 mg/l). Thereafter, serum creatinine con-
centration remained stable between 1.6 and 2.8mg/dl
(150–250 mmol/l). Four months after transplantation
and 10 days after therapy with OKT3, the patient
was admitted with fever, chills, myalgia and slight
right-sided neck pain. Laboratory tests showed normal
white blood cell count (7.8 109/l with 7.4 109/l
neutrophils and 0.15 109/l lymphocytes) and elevated
C-reactive protein (CRP) (78mg/l; normal: <5mg/l)
(Figure 1). Computed tomography (CT) of the chest
disclosed a small nodular lesion (Ø 1.2 cm) in the
left lower lobe and an inhomogeneous enlargement
of the right thyroid lobe. Fine needle aspiration of
the thyroid yielded Aspergillus fumigatus (minimum
inhibitory concentration: amphotericin B 0.5mg/l,
itraconazole 0.25mg/l). Aspergillus antigen (galacto-
mannan test) was positive (index: 2.2; normal: <1.0).
IA with involvement of thyroid and lung was diag-
nosed. Hemithyroidectomy was performed, tacrolimus
trough level lowered (from 10–15 to 7–10 mg/l), myco-
phenolate mofetil reduced (from 3000 to 2000mg daily)
and prednisone tapered within 4 weeks. Antifungal
therapy with amphotericin B lipid complex (5mg/kg
daily) was started. The patient remained febrile and
CRP did not decrease. Echocardiography and magnetic
resonance imaging (MRI) of the heart disclosed
myocardial abscesses and ﬁbrous pericarditis, suggest-
ing cardiac involvement of IA (Figure 2). Caspofungin
(50mg daily) and ﬂucytosin (4 3500mg daily) were
added to amphotericin B. Two weeks later, ﬂucytosin
was stopped due to leukopenia (2.7 109/l, 78%
neutrophils). Eleven weeks after the start of antifungal
combination therapy, the myocardial and pulmonary
lesions vanished, CRP normalized and Aspergillus
antigen became negative. The patient was discharged
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on oral itraconazole (3 200mg daily) for an addi-
tional 4 months. Due to the pharmacokinetic inter-
action between itraconazole and tacrolimus, we
reduced the dosage of tacrolimus from 2 to 0.5mg
twice daily. However, in spite of the reduction, trough
levels increased from 9 to 25 mg/l. Therefore, we paused
tacrolimus for 8 days and continued with a dosage
of 0.5mg once daily every other day to every third
day, achieving trough levels between 10 and 13 mg/l.
The increase of tacrolimus trough levels was accom-
panied by a temporary increase of the serum creati-
nine from 2.4mg/dl (220 mmol/l) to a peak value of
4.4mg/dl (389 mmol/l). The further clinical course
was uneventful until a slight increase of CRP (range:
12–38mg/l) was detected 6 weeks after stopping
itraconazole. Physical examination was unremarkable
and, in particular, no cardiac murmur was heard.
MRI of the heart, CT scan of the chest and galacto-
mannan test were normal. One month later, the patient
died unexpectedly of cardiac shock. Autopsy revealed
IA with endocarditis and rupture of the aortic valve,
myocardial fungal granuloma (Figure 3) and involve-
ment of lung and prostata. Culture of the aortic valve
yielded A. fumigatus.
Discussion
We report an unusual presentation of IA with predomi-
nant myocardial involvement 4 months after renal
transplantation. Major risk factors for IA include
prolonged neutropenia, chronic granulomatous disease
and the use of severe immunosuppressive regimens
and steroids [6]. Our patient was not neutropenic,
but severely immunosuppressed and lymphopenic
(<0.2 109/l). Severe long-lasting T-cell immuno-
suppression was caused by the treatment with ATG
and OKT3, leading to T-cell depletion and functional
T-cell alteration, by the use of tacrolimus in preventing
adequate cytokine release and T-cell activation and
by mycophenolate mofetil as an antiproliferative
agent [7,8]. Additionally, the activity of macrophages
and neutrophils, which are important in the phago-
cytosis of A. fumigatus, was altered by steroids [1].
As addressed by Singh et al. [9], antifungal attributes
of immunosuppressive drugs also are involved in the
pathogenesis of opportunistic mycosis. In vitro data
Fig. 2. Contrast-enhanced fat-suppressed T1-weighted turbo fast
low-angle shot (FLASH) image in the horizontal long axis of the
heart shows ﬁbrous pericarditis (arrows) and intramyocardial
abscesses (arrowheads).
Fig. 1. Clinical and laboratory course of IA. Galactomannan test performed retrospectively and galactomannan test performed prospectively.
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show a stronger anti-Aspergillus activity of tacrolimus
in contrast to cyclosporin. These data are supported
by animal studies. In a model of IA, mice immuno-
suppressed with tacrolimus or sirolimus developed
microabscesses with low hyphal burden, in contrast
with the widespread growth of hyphae in mice
treated with cyclosporin [10]. Interestingly, the autopsy
of our patient, who received tacrolimus, revealed a
pattern of microabscesses in the myocardium. In the
clinical setting of transplantation with overt fungal
infection, the immunosuppressive effects outweigh
the potential antifungal effect of immunosuppressive
drugs [9]. Other risk factors for IA, such as proximity
to a construction area or cytomegalovirus infection
[2,11], did not occur in our patient.
Myocarditis, pericarditis and endocarditis are rare
and fatal complications of disseminated aspergillosis,
diagnosed in most cases only at autopsy [12]. Early
diagnosis and prompt initiation of antifungal therapy
for presumed IA are essential to improve the outcome
of these patients. However, in contrast to neutro-
penic patients, for whom empirical antifungal therapy
is closely linked to the severity and duration of
neutropenia, there is no established clinical or labora-
tory marker in renal allograft recipients to start
empirical therapy. Recently, the detection of circulating
galactomannan, which is a component of the cell
wall of Aspergillus spp., by a sandwich enzyme-linked
immunosorbent assay in serum or respiratory speci-
mens has received considerable attention as a
valuable method for diagnosing IA [13]. However, the
usefulness of the galactomannan test for the early
diagnosis of IA remains controversial, because of high
speciﬁcity (>85%) but varying sensitivity between
29% and 100%, which is dependent on many factors
related to the host (underlying disease and immuno-
suppressive therapy, site of infection, age and exposure
to antifungal drugs) and to epidemiological character-
istics (prevalence of infection and patient popula-
tion) [14]. The combination of real-time polymerase
chain reaction with automated DNA-extraction and
galactomannan assay was shown recently to improve
the reliability of IA diagnosis [15], but these results
have to be conﬁrmed in larger trials.
The recent introduction of new antifungal agents,
such as voriconazole and caspofungin, offers new
opportunities in the treatment of IA. In patients with
IA, initial therapy with voriconazole led to better
responses and improved survival than the standard
approach with ampthotericin B [4] and, more recently,
caspofungin was shown to be as effective as and
better tolerated than liposomal amphotericin B when
given as empirical antifungal therapy in patients
with persistent fever and neutropenia [5]. Given the
different mechanism of action of caspofungin com-
pared with amphotericin B, a combination therapy
is promising. A synergistic effect of caspofungin and
amphotericin against Aspergillus spp. was demon-
strated in vitro [16]. Case reports showed a favourable
outcome for patients with invasive pulmonary asper-
gillosis refractory to amphotericin, treated with this
combination [17,18]. However, the role and efﬁcacy
of antifungal combination therapy in patients with
IA has not been established yet. Given the high
incidence and associated mortality of IA, a prophyl-
actic antifungal treatment with itraconazole [19]
would be a reasonable option. However, the threat
for emerging resistant strains and the potential drug
toxicity and interactions with the immunosuppressive
regimen make this approach unattractive for trans-
plant recipients.
Our case report highlights some of the unresolved
questions in the management of IA. Initially, the com-
bination therapy with amphotericin B and caspofungin
seemed to be effective. The patient recovered and
the myocardial and pulmonary lesions vanished radio-
logically. However, the unexpected death 10 weeks
after stopping a 6 month course of antifungal treat-
ment demonstrates that the therapy was only able to
suppress but not to eradicate Aspergillus infection,
as reﬂected by the histological pattern of myocar-
dial granuloma with central nestling of Aspergillus
hyphae. Despite a slight increase of CRP 1 month
before the patient died, we were not able to diagnose
a relapse of IA. Although radiological investigations
and Aspergillus antigen readings correlated with
clinical improvement under therapy, these tools were
not helpful for conﬁrming eradication or for detecting
the fatal relapse in our case. Therefore, a prolonged,
eventually lifelong antifungal suppressive therapy
should be considered for selected patients, even in
the absence of clinical and laboratory ﬁndings
suggestive for persistent IA.
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